142 related articles for article (PubMed ID: 17960966)
1. Early prediction of clinical response in schizophrenia patients receiving the atypical antipsychotic zotepine.
Lin CH; Chou LS; Lin CH; Hsu CY; Chen YS; Lane HY
J Clin Psychiatry; 2007 Oct; 68(10):1522-7. PubMed ID: 17960966
[TBL] [Abstract][Full Text] [Related]
2. Optimizing the early prediction model for symptomatic remission with short-term treatment for schizophrenia.
Lin CH; Chou LS; Lin CH; Hsu CY; Chen CC; Lane HY
J Clin Psychopharmacol; 2012 Dec; 32(6):773-7. PubMed ID: 23131876
[TBL] [Abstract][Full Text] [Related]
3. Optimizing early prediction for antipsychotic response in schizophrenia.
Chang YC; Lane HY; Yang KH; Huang CL
J Clin Psychopharmacol; 2006 Dec; 26(6):554-9. PubMed ID: 17110810
[TBL] [Abstract][Full Text] [Related]
4. A comparison of an atypical and typical antipsychotic, zotepine versus haloperidol in patients with acute exacerbation of schizophrenia: a parallel-group double-blind trial.
Petit M; Raniwalla J; Tweed J; Leutenegger E; Dollfus S; Kelly F
Psychopharmacol Bull; 1996; 32(1):81-7. PubMed ID: 8927680
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of zotepine for the treatment of Taiwanese schizophrenic patients: a double-blind comparison with haloperidol.
Hwang TJ; Lin SK; Lin HN
J Formos Med Assoc; 2001 Dec; 100(12):811-6. PubMed ID: 11802520
[TBL] [Abstract][Full Text] [Related]
6. Early prediction of antipsychotic response in schizophrenia.
Correll CU; Malhotra AK; Kaushik S; McMeniman M; Kane JM
Am J Psychiatry; 2003 Nov; 160(11):2063-5. PubMed ID: 14594760
[TBL] [Abstract][Full Text] [Related]
7. Early prediction of antipsychotic nonresponse among patients with schizophrenia.
Leucht S; Busch R; Kissling W; Kane JM
J Clin Psychiatry; 2007 Mar; 68(3):352-60. PubMed ID: 17388703
[TBL] [Abstract][Full Text] [Related]
8. Switching from clozapine to zotepine in patients with schizophrenia: a 12-week prospective, randomized, rater blind, and parallel study.
Lin CC; Chiu HJ; Chen JY; Liou YJ; Wang YC; Chen TT; Bai YM
J Clin Psychopharmacol; 2013 Apr; 33(2):211-4. PubMed ID: 23422395
[TBL] [Abstract][Full Text] [Related]
9. [Effectiveness of zotepine in therapy-refractory psychoses. An open, multicenter study in eight psychiatric clinics].
Harada T; Otsuki S; Fujiwara Y
Fortschr Neurol Psychiatr; 1991 Sep; 59 Suppl 1():41-4. PubMed ID: 1683339
[TBL] [Abstract][Full Text] [Related]
10. A placebo-controlled comparison of zotepine versus chlorpromazine in patients with acute exacerbation of schizophrenia.
Cooper SJ; Tweed J; Raniwalla J; Butler A; Welch C
Acta Psychiatr Scand; 2000 Mar; 101(3):218-25. PubMed ID: 10721870
[TBL] [Abstract][Full Text] [Related]
11. An open-label, randomized, controlled trial of zotepine and risperidone for acutely ill, hospitalized, schizophrenic patients with symptoms of agitation.
Chan HY; Lin AS; Chen KP; Cheng JS; Chen YY; Tsai CJ
J Clin Psychopharmacol; 2013 Dec; 33(6):747-52. PubMed ID: 24100785
[TBL] [Abstract][Full Text] [Related]
12. Switching to olanzapine after unsuccessful treatment with risperidone during the first episode of schizophrenia: an open-label trial.
Takahashi H; Kamata M; Yoshida K; Ishigooka J; Higuchi H
J Clin Psychiatry; 2006 Oct; 67(10):1577-82. PubMed ID: 17107250
[TBL] [Abstract][Full Text] [Related]
13. Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial.
Möller HJ; Riedel M; Müller N; Fischer W; Kohnen R
Pharmacopsychiatry; 2004 Nov; 37(6):270-8. PubMed ID: 15551193
[TBL] [Abstract][Full Text] [Related]
14. [Zotepine versus perazine in patients with paranoid schizophrenia: a double-blind controlled trial of its effectiveness].
Wetzel H; von Bardeleben U; Holsboer F; Benkert O
Fortschr Neurol Psychiatr; 1991 Sep; 59 Suppl 1():23-9. PubMed ID: 1683336
[TBL] [Abstract][Full Text] [Related]
15. Zotepine in the prevention of recurrence: a randomised, double-blind, placebo-controlled study for chronic schizophrenia.
Cooper SJ; Butler A; Tweed J; Welch C; Raniwalla J
Psychopharmacology (Berl); 2000 Jun; 150(3):237-43. PubMed ID: 10923750
[TBL] [Abstract][Full Text] [Related]
16. Early predictors of poor treatment response in patients with schizophrenia treated with atypical antipsychotics.
Chen YL; Chen KP; Chiu CC; Tai MH; Lung FW
BMC Psychiatry; 2018 Dec; 18(1):376. PubMed ID: 30509308
[TBL] [Abstract][Full Text] [Related]
17. Zotepine in the treatment of negative symptoms in chronic schizophrenia.
Fleischhacker WW; Barnas C; Stuppäck C; Unterweger B; Hinterhuber H
Pharmacopsychiatry; 1987 Feb; 20(1 Spec No):58-60. PubMed ID: 2883684
[TBL] [Abstract][Full Text] [Related]
18. Low-dose zotepine in the maintenance treatment of schizophrenia.
Fleischhacker WW; Stuppäck C; Barnas C; Unterweger B; Hinterhuber H
Pharmacopsychiatry; 1987 Feb; 20(1 Spec No):61-3. PubMed ID: 2883685
[TBL] [Abstract][Full Text] [Related]
19. [Effectiveness and tolerance of zotepine in a double-blind comparison with perazine in schizophrenic patients].
Dieterle DM; Müller-Spahn F; Ackenheil M
Fortschr Neurol Psychiatr; 1991 Sep; 59 Suppl 1():18-22. PubMed ID: 1683334
[TBL] [Abstract][Full Text] [Related]
20. Comparison of efficacy of zotepine and thiothixene in schizophrenia in a double-blind study.
Sarai K; Okada M
Pharmacopsychiatry; 1987 Feb; 20(1 Spec No):38-46. PubMed ID: 2883680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
